Publications by authors named "Barry A Singer"

Claim this Profile
L
Long-term efficacy and safety of alemtuzumab in participants with highly active MS: TOPAZ clinical trial and interim analysis of TREAT-MS real-world study.
Tjalf Ziemssen, Ann D Bass, Bart Van Wijmeersch, Sara Eichau, Stephan Richter, Barry A Singer

Ther Adv Neurol Disord· February 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Patient and Physician Perspectives of Treatment Burden in Multiple Sclerosis.
Barry A Singer, Dawn Morgan, Julie A Stamm, Anita A Williams

Neurol Ther· December 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Lymphopenia is Not the Primary Therapeutic Mechanism of Diroximel Fumarate in Relapsing-Remitting Multiple Sclerosis: Subgroup Analyses of the EVOLVE-MS-1 Study.
Barry A Singer, Sibyl Wray, Mark Gudesblatt, Barbara Bumstead, Tjalf Ziemssen

Neurol Ther· August 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Early use of high-efficacy therapies in multiple sclerosis in the United States: benefits, barriers, and strategies for encouraging adoption.
Barry A Singer, Jenny Feng, Horacio Chiong-Rivero

J Neurol· June 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Diroximel fumarate in patients with relapsing-remitting multiple sclerosis: Final safety and efficacy results from the phase 3 EVOLVE-MS-1 study.
Barry A Singer, Douglas L Arnold, Jelena Drulovic, Mark S Freedman, Ralf Gold

Mult Scler· December 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Safety and efficacy with alemtuzumab over 13 years in relapsing-remitting multiple sclerosis: final results from the open-label TOPAZ study.
Alasdair J Coles, Anat Achiron, Anthony Traboulsee, Barry A Singer, Carlo Pozzilli

Ther Adv Neurol Disord· September 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Durability of no evidence of disease activity-3 (NEDA-3) in patients receiving cladribine tablets: The CLARITY extension study.
Gavin Giovannoni, Barry A Singer, Delphine Issard, Dominic Jack, Patrick Vermersch

Mult Scler· July 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
H
Health-Related Quality of Life with Diroximel Fumarate in Patients with Relapsing Forms of Multiple Sclerosis: Findings from Qualitative Research Using Patient Interviews.
Mark Gudesblatt, Cortnee Roman, Barry A Singer, Hollie Schmidt, Jessica Thomas

Adv Ther· July 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Efficacy and Safety Outcomes with Diroximel Fumarate After Switching from Prior Therapies or Continuing on DRF: Results from the Phase 3 EVOLVE-MS-1 Study.
Sibyl Wray, Florian Then Bergh, Annette Wundes, Douglas L Arnold, Jelena Drulovic, Barry A Singer

Adv Ther· April 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A Study Comparing Patient and Clinician Perspectives of Treatments for Multiple Sclerosis via Group Concept Mapping.
Barry A Singer, Shannon Keith, Amy Howerter, Helen Doll, Timothy Pham

Patient Prefer Adherence· May 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Improved gastrointestinal profile with diroximel fumarate is associated with a positive impact on quality of life compared with dimethyl fumarate: results from the randomized, double-blind, phase III EVOLVE-MS-2 study.
Annette Wundes, Sibyl Wray, Ralf Gold, Barry A Singer, Elzbieta Jasinska

Ther Adv Neurol Disord· March 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Efficacy of alemtuzumab in relapsing-remitting MS patients who received additional courses after the initial two courses: Pooled analysis of the CARE-MS, extension, and TOPAZ studies.
Giancarlo Comi, Raed Alroughani, Aaron L Boster, Ann D Bass, Regina Berkovich, Barry A Singer

Mult Scler· December 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
Q
Quality of Life Improves with Alemtuzumab Over 6 Years in Relapsing-Remitting Multiple Sclerosis Patients with or without Autoimmune Thyroid Adverse Events: Post Hoc Analysis of the CARE-MS Studies.
Antonio Bertolotto, Rafael Arroyo, Elisabeth G Celius, Giancarlo Comi, Eva Kubala Havrdova, Barry A Singer

Neurol Ther· December 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Efficacy of alemtuzumab over 6 years in relapsing-remitting multiple sclerosis patients who relapsed between courses 1 and 2: Post hoc analysis of the CARE-MS studies.
Bart Van Wijmeersch, Barry A Singer, Aaron Boster, Simon Broadley, Óscar Fernández

Mult Scler· November 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Efficacy and Safety of Alemtuzumab Through 9 Years of Follow-up in Patients with Highly Active Disease: Post Hoc Analysis of CARE-MS I and II Patients in the TOPAZ Extension Study.
Tjalf Ziemssen, Ann D Bass, Regina Berkovich, Giancarlo Comi, Sara Eichau, Barry A Singer

CNS Drugs· September 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Efficacy and Safety of 2 Fingolimod Doses vs Glatiramer Acetate for the Treatment of Patients With Relapsing-Remitting Multiple Sclerosis: A Randomized Clinical Trial.
Bruce A C Cree, Myla D Goldman, John R Corboy, Barry A Singer, Edward J Fox

JAMA Neurol· August 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Clinical and MRI efficacy of sc IFN β-1a tiw in patients with relapsing MS appearing to transition to secondary progressive MS: post hoc analyses of PRISMS and SPECTRIMS.
Mark S Freedman, Staley Brod, Barry A Singer, Bruce A Cohen, Brooke Hayward

J Neurol· January 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The role of natalizumab in the treatment of multiple sclerosis: benefits and risks.
Barry A Singer

Ther Adv Neurol Disord· September 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Survey of US Patients with Multiple Sclerosis: Comparison of the New Electronic Interferon Beta-1b Autoinjector (BETACONNECT™) With Mechanical Autoinjectors.
Donald A Barone, Barry A Singer, Lubo Merkov, Mark Rametta, Gustavo Suarez

Neurol Ther· December 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Parenteral Treatment of Multiple Sclerosis: The Advent of Monoclonal Antibodies.
Barry A Singer

Semin Neurol· April 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Initiating oral fingolimod treatment in patients with multiple sclerosis.
Barry A Singer

Ther Adv Neurol Disord· July 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
F
Fingolimod for the treatment of relapsing multiple sclerosis.
Barry A Singer

Expert Rev Neurother· June 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Rapid onset mitoxantrone-induced cardiotoxicity in secondary progressive multiple sclerosis.
Jagannadha R Avasarala, Anne H Cross, David B Clifford, Barry A Singer, Barry A Siegel

Mult Scler· February 2003

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis